Showing results (61-70 of 90) with videos related to
Sort By:
Pageof 9
Blood|April 1, 2011
Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasLPratima Sinha, Olesya Chornoguz, Virginia K Clements, et al.Journal of Leukocyte Biology|January 19, 2018
Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cellsVirginia K Clements, Tiha Long, Ramses Long, et al.Cancer Immunology, Immunotherapy : CII|November 1, 2003
Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic diseaseSuzanne Ostrand-Rosenberg, Pratima Sinha, Virginia Clements, et al.Journal of Leukocyte Biology|August 30, 2014
Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumorsDaniel W Beury, Katherine H Parker, Maeva Nyandjo, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2002
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependentSuzanne Ostrand-Rosenberg, Virginia K Clements, Masaki Terabe, et al.Cancer Research|January 21, 2006
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chainJames A Thompson, Samudra K Dissanayake, Bruce R Ksander, et al.Proteomics|May 20, 2016
Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathwaysWaeowalee Choksawangkarn, Lauren M Graham, Meghan Burke, et al.Cancer Immunology, Immunotherapy : CII|March 7, 2008
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsMinu K Srivastava, Jacobus J Bosch, James A Thompson, et al.Cancer Immunology, Immunotherapy : CII|August 29, 2007
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytesJames A Thompson, Minu K Srivastava, Jacobus J Bosch, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2004
Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccinesBrian P Dolan, Timothy P Phelan, Dan Ilkovitch, et al.Pageof 9